Home | Welcome to Contract Pharma   
Last Updated Thursday, December 18 2014

Print RSS Feed

ProBioGen, Merus Sign GlymaxX License Agreement



By Kristin Brooks



Published March 4, 2014
Related Searches: Development
ProBioGen AG and Merus B.V. have signed a non-exclusive commercial option and license agreement granting Merus access to ProBioGen’s GlymaxX fucose-engineering technology to enhance the ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity for its lead product, a bispecific anti-cancer antibody. The license covers clinical development and production. Financial details were not disclosed.
 
"We are very satisfied to see our GlymaxX technology being applied to Merus’ promising bispecific cancer antibody candidate. This underlines the superiority of our ADCC enhancement technology and its ability to deliver smart and flexible solutions for optimized biopharmaceutical products," said Volker Sandig, chief scientific officer of ProBioGen AG. “We are convinced that our GlymaxX technology will make a significant contribution to develop powerful new antibodies against any diseases in which enhanced ADCC activity translates into therapeutic benefit.”
 
“The GlymaxX technology substantially improves the ADCC activity of one of our lead bispecific antibodies for the treatment of solid tumors so that it further enhances the tumor cell killing capacity of an already very potent molecule,” said Mark Throsby, chief scientific officer of Merus B.V.


blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On